Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Drug Patent Reform’s Often Been Postponed, Is Congress Ready To Act?
Health and Wellness

Drug Patent Reform’s Often Been Postponed, Is Congress Ready To Act?

Last updated: April 6, 2025 10:21 am
Share
Drug Patent Reform’s Often Been Postponed, Is Congress Ready To Act?
SHARE

The Senate Judiciary Committee recently made significant progress by moving forward with six bills aimed at addressing prescription drug pricing, particularly focusing on overhauling the patent system. This marks a milestone in a long-standing issue that has bipartisan support but has struggled to make any real changes in the past. The urgency surrounding this issue is palpable, with both constituents and policymakers pushing for action. However, given the history of failed attempts to pass reform, there is still uncertainty about whether the 119th Congress is truly prepared to take action.

Congress’s approval rating of 29% reflects a lack of effectiveness in getting things done, especially in healthcare policy. Reforms related to Pharmacy Benefit Managers and drug patents have often been delayed or ignored, leaving many stakeholders frustrated. The influence of lobbyists and general inertia within Congress have contributed to the stagnation of these critical issues.

Despite the challenges of finding bipartisan consensus in today’s political landscape, there is a widespread agreement on the need for pharmaceutical patent reform. The high prices of brand-name drugs in the U.S. are partly attributed to tactics used by drug manufacturers to prolong their monopoly pricing and block competition from generic alternatives. Former FDA Commissioner Scott Gottlieb and former Federal Trade Commissioner Lina Khan have both highlighted the need to address these anticompetitive practices.

Patients For Affordable Drugs NOW founder, David Mitchell, a cancer patient himself, has been vocal about the anticompetitive tactics employed by drug companies to maintain monopolies. Additionally, the Initiative for Medicines, Access & Knowledge advocates for drug patent reform, citing the detrimental impact of excessive patent use on medication prices for American patients.

See also  Updated drug information handout outdoes FDA's version in clinical trial

Studies have shown that a significant number of new drug patents are for existing medications, and many best-selling drugs receive additional patents to extend their market exclusivity. This practice, known as “evergreening,” contributes to high drug costs and limits access to more affordable generic alternatives.

While the pharmaceutical industry argues that patent reform is unnecessary due to the prevalence of generics in the market, lawmakers are keen on curbing abuses of the system. Recent legislative efforts have focused on addressing anti-competitive practices and promoting a more competitive market for generics and biosimilars.

The Senate Judiciary Committee’s advancement of six bills targeting drug pricing and patent reform is a positive step forward. These bills aim to tackle issues such as “patent thickets” and “product hopping,” as well as limiting pay-for-delay deals and sham citizen petitions that hinder generic drug approvals. Despite past setbacks, there is hope that meaningful changes may finally be on the horizon in this Congress. Only time will tell if these efforts will lead to tangible reform in the prescription drug pricing landscape.

TAGGED:ActCongressDrugpatentPostponedreadyreforms
Share This Article
Twitter Email Copy Link Print
Previous Article Jesse Watters Shares Creepy ‘Deep Dive’ On Elon Musk’s Ex-Girlfriends Jesse Watters Shares Creepy ‘Deep Dive’ On Elon Musk’s Ex-Girlfriends
Next Article Boston Faces Identity Crisis Amid Trump’s Cuts to University and Research Funding Boston Faces Identity Crisis Amid Trump’s Cuts to University and Research Funding
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

U.S.-China trade talks continue on day 2 in London : NPR

Chinese Vice Premier He Lifeng, center right, and U.S. Treasury Secretary Scott Bessent, center left,…

June 10, 2025

‘Real Housewives of London’ Coming in 2025 as Hayu’s First Original

The Real Housewives Franchise Expands to London The popular “Real Housewives” franchise is set to…

October 26, 2024

President Trump Announces Appointments to the Council of Governors – The White House

President Trump Announces New Appointments to the Council of Governors Today, President Donald J. Trump…

February 20, 2025

Uber, Lyft drivers have been robbed 8 times on the same Chicago street, police say

Chicago police have issued a warning to Lyft and Uber drivers in the South Shore…

September 14, 2024

Measles Cases Surpass 300 In Texas, New Mexico: Here’s What You Should Know

Measles outbreaks in West Texas and New Mexico have reached nearly 320 cases, with two…

March 18, 2025

You Might Also Like

Remission achievable for 1 in 3 Indian diabetics through intensive app-based lifestyle program, study suggests
Health and Wellness

Remission achievable for 1 in 3 Indian diabetics through intensive app-based lifestyle program, study suggests

October 31, 2025
Once Again A Blood Pressure Medication Recall For Cancer Concerns
Health and Wellness

Once Again A Blood Pressure Medication Recall For Cancer Concerns

October 31, 2025
IVF research, FDA vouchers, dementia: Morning Rounds
Health and Wellness

IVF research, FDA vouchers, dementia: Morning Rounds

October 31, 2025
Nearly 1 in 5 urinary tract infections linked to contaminated meat
Health and Wellness

Nearly 1 in 5 urinary tract infections linked to contaminated meat

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?